Quidel - Stock Of The Day

Summary

• 100% technical buy signals.
• 11 new highs and up 37.96% in the last month.
• 43.12% gain in the last year.

The Barchart Chart of the Day belongs to the medical products company Quidel (QDEL).I found the stock by using Barchart's powerful screening tools to find a list of stock with the highest Weighted Alpha and highest technical buy signals - by the way that narrowed the list of approximately 12,000 stock in the data base to just 16 choices.I then sorted that short list by the most frequent number of new highs in the last month; then used the Flipchart feature to review the charts for consistent price appreciation.Since the Trend signaled a buy on 3/17 the stock gained 4.45%.

Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women's health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis.

Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart technical indicators:

• 100% technical buy signals
• 51.69+ Weighted Alpha
• 43.12% gain in the last year
• Trend Spotter buy signa
• Above its 20, 50 and 100 day moving averages
• 11 new highs and up 37.96% in the last month
• Relative Strength Index 59.12%
• Technical support level at 96.16
• Recently traded at 97.01 with a 50 day moving average of 81.92

Fundamental factors:

• Market Cap $4.34 billion
• P/E 34.67
• Revenue expected to grow 3.50% this year and another 5.0% next year
• Earnings estimated to increase 2.40% this year, an additioanl 9.90% next year and continue to compound at an annual rate of 7.20% for the next 5 years
• Wall Street analysts issued 2 strong buy, 3 buy and 2 hold recommendations on the stock
• The individual investors following the stock on Motley Fool voted 192 to 9 that the stock will beat the market
• 2,664 investors are monitoring the stock on Seeking Alpha